TNGXTango Therapeutics, Inc.

TNGX Stock Price, Valuation & Chart | Tango Therapeutics, Inc.

Compare

$22.320-0.03 (-0.13%)

At close · 02 Sept 2026, 08:00 pm

Sector: Healthcare Industry: Biotechnology TNGX intrinsic value TNGX calculated fair value vs price

Overview Financials Dividends Ratios

TNGX Historical price chart

TNGX Key Stats

Fair Value

Disclaimer

Disclaimer: This fair value estimate is for informational purposes only and should not be considered as investment advice. Fair value calculations are based on DCF (Discounted Cash Flow), P/E Multiple, and P/S Multiple models and assumptions that may not reflect actual market conditions. Always conduct your own research and consult with a financial advisor before making investment decisions.

Unlock

Market Capitalization3.63B

PE Ratio-26.89

EPS-0.83

Trading Volume1.92M

Today's High/Low23.12/21.65

Dividend Yield0.00

52 Week High/Low34.39/6.25

Shares Outstanding162.81M

TNGX Financial Statement

TNGX Analyst ratings

TNGX Analysis & performance metrics

TNGX Company profile

Tango Therapeutics, Inc., a biotechnology company, discovers and develops drugs for the treatment of cancer. Its lead program is TNG908, a synthetic lethal small molecule…

Tango Therapeutics, Inc., a biotechnology company, discovers and develops drugs for the treatment of cancer. Its lead program is TNG908, a synthetic lethal small molecule inhibitor of protein arginine methyltransferase 5 that is being developed as a treatment for cancers with methylthioadenosine phosphorylase deletions. The company also develops Ubiquitin-specific protease 1, an…

TNGX Management team

Name

Position

Daniella Beckman CPACFO

Chief Financial Officer

Douglas J. Barry Esq., J.D.

Chief Legal Officer, Chief Compliance Officer & Corporate Secretary

Julie Carretero

Chief Human Resources Officer

Adam S. Crystal M.D., Ph.D.

President of Research & Development

William G. Kaelin Jr., M.D.

Founder & Member of Scientific Advisory Board

Michael Palmieri Ph.D.

Head of Technical Operations

Jannik N. Andersen Ph.D.

Chief Scientific Officer

Elizabeth Pingpank Hickin

Vice President of IR & Corporate Communications

Name

Position

Daniella Beckman CPACFO

Chief Financial Officer

Douglas J. Barry Esq., J.D.

Chief Legal Officer, Chief Compliance Officer & Corporate Secretary

Julie Carretero

Chief Human Resources Officer

Adam S. Crystal M.D., Ph.D.

President of Research & Development

William G. Kaelin Jr., M.D.

Founder & Member of Scientific Advisory Board

Michael Palmieri Ph.D.

Head of Technical Operations

Jannik N. Andersen Ph.D.

Chief Scientific Officer

Elizabeth Pingpank Hickin

Vice President of IR & Corporate Communications

Management Team

Daniella Beckman CPACFO

Chief Financial Officer

Douglas J. Barry Esq., J.D.

Chief Legal Officer, Chief Compliance Officer & Corporate Secretary

Julie Carretero

Chief Human Resources Officer

Adam S. Crystal M.D., Ph.D.

President of Research & Development

William G. Kaelin Jr., M.D.

Founder & Member of Scientific Advisory Board

Michael Palmieri Ph.D.

Head of Technical Operations

Jannik N. Andersen Ph.D.

Chief Scientific Officer

Elizabeth Pingpank Hickin

Vice President of IR & Corporate Communications

Management

Daniella Beckman CPACFO

Chief Financial Officer

Douglas J. Barry Esq., J.D.

Chief Legal Officer, Chief Compliance Officer & Corporate Secretary

Julie Carretero

Chief Human Resources Officer

Adam S. Crystal M.D., Ph.D.

President of Research & Development

William G. Kaelin Jr., M.D.

Founder & Member of Scientific Advisory Board

Michael Palmieri Ph.D.

Head of Technical Operations

Jannik N. Andersen Ph.D.

Chief Scientific Officer

Elizabeth Pingpank Hickin

Vice President of IR & Corporate Communications

Total 8 executives

TNGX Frequently asked questions

What is Tango Therapeutics, Inc. (TNGX) Stock Price?

Current stock price of Tango Therapeutics, Inc. (TNGX) stock is $22.320. The stock price is -0.13% lower in the session. The intraday range can be seen from this page. Volume of Tango Therapeutics, Inc. (TNGX) stock is 1.92M.

Last updated at 02 Sept 2026, 08:00 pm.

Why is the Tango Therapeutics, Inc. (TNGX) stock price going up or down today?

The stock price of Tango Therapeutics, Inc. (TNGX) can change with earnings, company news, and overall market sentiment. Tango Therapeutics, Inc. operates in the Healthcare / Biotechnology market, so sector-wide moves can also affect the share price. Use the live price, percentage change, and volume on this page to judge whether a move looks meaningful.

Is the Tango Therapeutics, Inc. stock expensive at its current price?

Whether Tango Therapeutics, Inc. looks expensive depends on valuation metrics versus its growth outlook. The P/E ratio shown for TNGX on this page is -26.89. EPS on this page is -0.83. Compare those figures with peers and growth expectations before deciding if the current Tango Therapeutics, Inc. price is justified.

How has the stock price of Tango Therapeutics, Inc. (TNGX) performed historically?

Historical performance for Tango Therapeutics, Inc. (TNGX) is shown on the price chart on this page. Review multi-period moves alongside volume to see how TNGX reacted to past earnings and market events.

Should I buy Tango Therapeutics, Inc. (TNGX) stock, at this price?

Buying Tango Therapeutics, Inc. (TNGX) depends on your risk tolerance, time horizon, and portfolio needs. As a Healthcare name, weigh the live quote, key stats, and valuation links on this page rather than a single price point.